Israeli startup QuantHealth has secured $15 million in Series A funding to fuel its US expansion. Co-led by Bertelsmann Investments and Pitango HealthTech, the funding will support the startup's clinical trial simulator platform, which employs artificial intelligence (AI) to predict patient responses to treatment. By simulating thousands of variations, the platform optimizes trial design and drug development for pharma, biotech, and life sciences companies. The AI simulator, trained on extensive patient and therapeutic data, boasts an 86% accuracy rate in predicting clinical trial results. This innovation has the potential to accelerate drug discovery and development, leading to improved and more cost-effective therapies.
QuantHealth's platform addresses the challenges of drug development, where lengthy trials and high costs often result in low success rates. By leveraging AI, the startup aims to enhance the efficiency and effectiveness of clinical trials, ultimately benefiting patients worldwide.
With a focus on expanding into the US market, QuantHealth aims to bridge gaps in clinical research and provide solutions that lead to faster drug approvals and improved patient outcomes. The integration of AI into drug discovery and development holds significant promise, offering a lucrative sales opportunity in the pharmaceutical industry over the next decade.
By offering AI-powered solutions that streamline clinical trials and drug development, QuantHealth contributes to the advancement of medical research and the acceleration of life-saving treatments to market.